/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | GRDNGuardian Pharmacy Se |
|---|---|
| Last close | $42.39close 2026-11-06 |
| Change % | +6.32%close 2026-11-06 |
| Market cap | $2.7Bclose 2026-11-06 |
| P/E | no EPS filed |
| Revenue | $1.4B⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldRevenues As ofFY ending 2025-12-31 |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.
| Rev growth (YoY) | 17.9%FY to 2025-12-31 |
| Net income | $49M⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldNetIncomeLoss As ofFY ending 2025-12-31 Filing10-K · 0001193125-26-102172 · filed 2026-03-11 Open the filing on EDGAR →Open the XBRL payload →CiteGuardian Pharmacy Services, Inc. (GRDN), us-gaap:NetIncomeLoss: 49,219,000 USD, fiscal year ended 2025-12-31. Form 10-K, accession 0001193125-26-102172, filed 2026-03-11. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001802255/us-gaap/NetIncomeLoss.json |
| Net margin | 3.4%FY to 2025-12-31 |
| EPS (diluted) | no EPS filed |
| Piotroski F-ScoreUNVALIDATED | 6FY to 2025-12-31 |
| Altman Z-ScoreUNVALIDATED | 12.84FY to 2025-12-31 |
| Beneish M-ScoreUNVALIDATED | -2.95FY to 2025-12-31 |
| Next earnings | 03-05 → 03-15 |